Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

NCT05676073 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

NETWORK

Sponsor class

Conditions

COVID-19

Interventions

DRUG: SHEN26 dose 1
DRUG: SHEN26 dose 2
DRUG: SHEN26 placebo

Sponsor

Shenzhen Kexing Pharmaceutical Co., Ltd.